Breaking News Instant updates and real-time market news.

SCHW

Charles Schwab

$31.01

-0.72 (-2.27%)

, ICE

IntercontinentalExchange

$265.21

-2.125 (-0.79%)

10:55
10/13/16
10/13
10:55
10/13/16
10:55

Barclays financial services analysts hold an analyst/industry conference call

Analysts provide a preview of Financial Services 3Q earnings on an Analyst/Industry conference call to be held on October 13 at 11 am.

SCHW

Charles Schwab

$31.01

-0.72 (-2.27%)

ICE

IntercontinentalExchange

$265.21

-2.125 (-0.79%)

CME

CME Group

$104.27

0.34 (0.33%)

NDAQ

Nasdaq

$66.46

0.52 (0.79%)

AMTD

TD Ameritrade

$35.70

-0.01 (-0.03%)

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 03

    Nov

SCHW Charles Schwab
$31.01

-0.72 (-2.27%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
BOFA
10/13/16
UPGRADE
Target $38
BOFA
Buy
Charles Schwab upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded Charles Schwab to Buy and raised its price target to $38 from $32. The analyst sees upside from higher interest rates given Schwab's exposure to money markets and portfolio duration and from other strategic factors including M&A activity and/or competitive/pricing. Further, Carrier said Schwab has strong organic growth, less pressure from competition, is well positioned for DOL, and can balance revenue and expense growth.
09/30/16
WELS
09/30/16
NO CHANGE
WELS
Multiple companies could pursue Scottrade, says Wells Fargo
After Bloomberg reported that Scottrade is working with an adviser to explore selling itself, and the article mentioned Ameritrade (AMTD) as a potential suitor, Wells Fargo says that Charles Schwab (SCHW) and E-Trade (ETFC) could "also have interest" in Scottrade. The firm says that the deal could be accretive by double digit percentage levels for all of the potential suitors named. However, ti says that Ameritrade "may be the most logical buyer," since E-Trade just closed on an acquisition and Schwab has sought to place less emphasis trading. The firm keeps an Outperform rating on E-Trade and Market Perform ratings on Schwab and TD Ameritrade.
09/26/16
09/26/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Apache (APA) initiated with a Neutral at MUFG. 2. Marriott (MAR) was initiated with a Buy at Goldman while the firm initiated La Quinta (LQ) with a Sell. Goldman also initiated Red Rock Resorts (RRR), Hyatt (H), and Wyndham (WYN) with a Neutral. 3. Charles Schwab (SCHW) was initiated with an Overweight at Morgan Stanley while the firm initiated E-Trade (ETFC) and TD Ameritrade (AMTD) with an Equal Weight. 4. Valvoline (VVV) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ICE IntercontinentalExchange
$265.21

-2.125 (-0.79%)

08/04/16
UBSW
08/04/16
NO CHANGE
Target $314
UBSW
Buy
IntercontinentalExchange price target raised to $314 from $279 at UBS
UBS raised its price target on IntercontinentalExchange to $314 from $279 as they believe the company is clicking on all cylinders. The firm cited strong Market Data growth, share repurchases, and growth in non-transactional revenues. UBS reiterated its Buy rating on IntercontinentalExchange shares.
05/20/16
05/20/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top analyst initiations with this list compiled by The Fly: 1. IntercontinentalExchange (ICE) initiated with a Buy at Sterne Agee CRT by analyst Jason Weaver, who put a $300 price target on shares. The firm has a positive view of what it sees as the company's "leading position and growth trajectory in energy, equity, and fixed income trading and clearing." The firm adds that the company's revenue mix is less volatile than its peers, while synergies and cost controls have made the company more profitable. Weaver also initiated Nasdaq (NDAQ) with a Buy rating and $76 price target, CME Group (CME) with a Neutral rating and $90 price target and CBOE Holdings (CBOE) with an Underperform rating and $56 price target. 2. Akari Therapeutics (AKTX) initiated with a Buy rat Canaccord. The firm set a $33 price target on shares and cited expectations for FDA product approvals and a level of underappreciation by investors for its shares. 3. Ralph Lauren (RL) initiated with a Buy and $115 price target by BB&T analyst Corinna Freedman, who believes Ralph Lauren will be successful in its turnaround and gain relevancy among a new younger demographic due to its strong vertical global brand house with a powerful heritage and sees significant category opportunities remaining in Women's and Accessories. Additionally, Freedman said International growth opportunities remain and Club Monaco repositioning is underappreciated. 4. Johnson & Johnson (JNJ) initiated with a Sell at Standpoint Research and $94 target. 5. PACCAR (PCAR) initiated with a Hold at Argus. The firm said it expects challenging industry conditions to pressure earnings through 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here
06/01/16
JPMS
06/01/16
DOWNGRADE
Target $284
JPMS
Neutral
IntercontinentalExchange resumed with Neutral from Overweight at JPMorgan
JPMorgan analyst Kenneth Worthington downgraded IntercontinentalExchange to Neutral after resuming coverage of the name following a period of restriction. The analyst expects the decline in the company's return on invested capital to weigh on the valuation. He has a $284 price target for the shares.
09/23/16
RBCM
09/23/16
NO CHANGE
RBCM
CBOE 'likely in the cross-hairs' of bigger peers, says RBC Capital
RBC Capital analyst Andrew Bond said he thinks the strategic risk of a deal whereby CBOE (CBOE) buys Bats Global Markets (BATS), as it has been reported to be in talks to do, outweighs the potential reward. However, he also believe CBOE's relatively small size, limited regulatory risk, clean balance sheet, and strong organic growth make it an attractive target for its largest exchange peers, such as IntercontinentalExchange (ICE) and CME Group (CME). A combined CBOE/BATS would be more difficult to acquire, so if CBOE is to be acquired, "the time is now," added Bond.
CME CME Group
$104.27

0.34 (0.33%)

08/31/16
JEFF
08/31/16
NO CHANGE
Target $118
JEFF
Buy
CME Group price target raised to $118 from $112 at Jefferies
Jefferies analyst Daniel Fannon raised his price target for CME Group to $118 after traveling with management. The analyst says the diversity of CME's growth continues and he keeps a Buy rating on the shares.
09/12/16
JPMS
09/12/16
NO CHANGE
Target $116
JPMS
Overweight
CME Group price target raised to $116 from $106 at JPMorgan
JPMorgan analyst Kenneth Worthington raised his price target for CME Group to $116 saying the company's product mix benefits from the current market environment. The analyst sees further share upside and keeps an Overweight rating on CME.
NDAQ Nasdaq
$66.46

0.52 (0.79%)

05/19/16
05/19/16
INITIATION
Target $76

Buy
Nasdaq initiated with a Buy at Sterne Agee CRT
Sterne Agee CRT analyst Jason Weaver initiated Nasdaq with a Buy rating and $76 price target on shares.
05/20/16
05/20/16
NO CHANGE

Nasdaq initiated at Sterne Agee CRT
As noted earlier, Sterne Agee CRT initiated Nasdaq with a Buy rating and $76 price target. The firm says that the company has diverse revenue streams that have growth potential, while it has "growing potential" in equities and equity derivatives.
07/05/16
EVER
07/05/16
DOWNGRADE
EVER
Hold
Nasdaq downgraded to Hold from Buy at Evercore ISI
Evercore ISI analyst Warren Gardiner downgraded Nasdaq to Hold and lowered its price target to $68 from $69. The analyst downgraded shares citing relative valuation and market share pressure in both US options and US cash equities. Gardiner said BATS/MIAX are approaching launch dates for their complex option venues, which will likely take share.
AMTD TD Ameritrade
$35.70

-0.01 (-0.03%)

09/30/16
SBSH
09/30/16
NO CHANGE
Target $31.5
SBSH
Neutral
Citi 'inclined to fade' September rally in TD Ameritrade
Citi analyst William Katz attributes the 5% September rally in shares of TD Ameritrade (AMTD) to speculation around a possible acquisition of E-Trade (ETFC). The rally in the shares likely discounts the earnings accretion from such a merger, Katz tells investors in a research note. He believes TD Ameritrade shares at current levels leave "no room for a bad outcome," which he defines as the company deciding not to pursue the deal or E-Trade acquiring Scottrade. As such, Katz says he's "inclined to fade the rally" in TD Ameritrade. The analyst has a Neutral rating on the shares with a $31.50 price target. TD Ameritrade is up 2% in early trading to $35.08.
10/13/16
BOFA
10/13/16
UPGRADE
Target $43
BOFA
Buy
TD Ameritrade upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded TD Ameritrade (AMTD) to Buy and raised its price target to $43 from $33. The analyst sees upside from higher interest rates given TD Ameritrade's exposure to the curve and from other strategic factors including M&A activity and/or competitive/pricing. Carrier said M&A speculation in the space is picking up and said its plausible for TD Ameritrade to acquire privately held Scottrade and/or E-Trade (ETFC).

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.63

-1.24 (-1.04%)

22:25
12/04/16
12/04
22:25
12/04/16
22:25
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

AAPL

Apple

$109.90

0.41 (0.37%)

, ALNY

Alnylam

$41.57

-0.01 (-0.02%)

21:48
12/04/16
12/04
21:48
12/04/16
21:48
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$109.90

0.41 (0.37%)

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

UTX

United Technologies

$108.22

0.74 (0.69%)

RXN

Rexnord

$20.27

-0.72 (-3.43%)

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

EVC

Entravision

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

DE

Deere

$101.50

-1.2 (-1.17%)

ARCH

Arch Coal

$79.32

1.6 (2.06%)

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

MRK

Merck

$61.13

0.37 (0.61%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

  • 15

    Jan

  • 08

    Mar

  • 13

    Mar

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$85.62

0.15 (0.18%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
Citrix rating change  »

Citrix upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 08

    Dec

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.